MESOBLAST LTD
NASDAQ: MESO (Mesoblast Limited)
Kemas kini terakhir: 2 hari lalu, 9:08PM17.87
0.68 (3.96%)
| Penutupan Terdahulu | 17.19 |
| Buka | 17.56 |
| Jumlah Dagangan | 220,070 |
| Purata Dagangan (3B) | 235,188 |
| Modal Pasaran | 2,300,686,592 |
| Harga / Pendapatan (P/E Ke hadapan) | 454.55 |
| Harga / Jualan (P/S) | 119.53 |
| Harga / Buku (P/B) | 3.70 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 28 Aug 2025 |
| Margin Operasi (TTM) | -633.21% |
| EPS Cair (TTM) | -1.24 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -6.80% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 27.34% |
| Nisbah Semasa (MRQ) | 0.960 |
| Aliran Tunai Operasi (OCF TTM) | -42.54 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -13.46 M |
| Pulangan Atas Aset (ROA TTM) | -4.85% |
| Pulangan Atas Ekuiti (ROE TTM) | -21.31% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Mesoblast Limited | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | 5.0 |
| Osilator Teknikal | 4.0 |
| Purata | 1.63 |
|
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 0.06% |
| % Dimiliki oleh Institusi | 3.10% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Summit X, Llc | 30 Jun 2025 | 199,295 |
| Rockbridge Investment Management, Lcc | 30 Sep 2025 | 49,150 |
| Lazari Capital Management, Inc. | 30 Sep 2025 | 46,671 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |